Junshi Biosciences

Core Business Focus

Junshi Biosciences concentrates on developing first-in-class and best-in-class therapeutics across several major disease areas. The company's research and development efforts span the entire drug development value chain, from early-stage discovery through clinical development, manufacturing, and commercialization. Its principal therapeutic areas include:

• Oncology and cancer immunotherapy
• Autoimmune and inflammatory diseases
• Metabolic disorders
• Neurological conditions
• Infectious diseases, including antiviral therapeutics

A defining feature of Junshi's strategy is its emphasis on originality. The company invests heavily in in-house research capabilities rather than relying solely on in-licensed assets, positioning it as a genuine innovator within the Chinese and global biopharmaceutical landscape.

Flagship Products

Toripalimab (Tuoyi / LOQTORZI)

Junshi Biosciences' most notable product is toripalimab, a programmed death receptor-1 (PD-1) monoclonal antibody. Toripalimab was the first domestically developed anti-PD-1 monoclonal antibody approved for marketing in China, receiving approval from China's National Medical Products Administration (NMPA) in December 2018 under the brand name Tuoyi.

Toripalimab is an immune checkpoint inhibitor used in cancer immunotherapy. It works by blocking the PD-1 receptor on immune cells, thereby helping the body's immune system recognize and attack cancer cells. The drug has been approved for multiple indications, including:

• Melanoma
• Nasopharyngeal carcinoma
• Urothelial carcinoma
• Esophageal squamous cell carcinoma
• Non-small cell lung cancer

A major milestone for the company came in October 2023 when toripalimab received approval from the U.S. Food and Drug Administration (FDA) under the brand name LOQTORZI for the treatment of nasopharyngeal carcinoma. This made toripalimab the first China-developed and manufactured innovative biologic drug of its kind to gain FDA approval, marking a significant achievement for both Junshi and the broader Chinese biopharmaceutical industry.

Anti-COVID-19 Therapeutics

Junshi Biosciences played an active role during the COVID-19 pandemic, developing neutralizing antibody therapies. The company collaborated on etesevimab (JS016), a neutralizing monoclonal antibody used in combination with bamlanivimab, developed in partnership with Eli Lilly and Company. Junshi also developed VV116, an oral antiviral drug for the treatment of COVID-19.

Product Pipeline

Beyond its marketed products, Junshi Biosciences maintains a broad and diverse pipeline of investigational drug candidates. The company's pipeline includes numerous monoclonal antibodies, antibody-drug conjugates (ADCs), bispecific antibodies, and small molecule drugs at various stages of clinical and preclinical development. Key areas of pipeline development include:

• Additional immuno-oncology candidates targeting novel checkpoints and tumor-associated antigens
• Therapeutics for autoimmune diseases such as psoriasis and inflammatory conditions
• Anti-BLyS (B-lymphocyte stimulator) antibodies for systemic lupus erythematosus
• PCSK9 inhibitors for the treatment of hypercholesterolemia and cardiovascular risk reduction
• Anti-interleukin therapies for various inflammatory disorders

The company's pipeline reflects a balanced approach between oncology and non-oncology indications, ensuring diversification across multiple therapeutic domains.

Research and Development Capabilities

Junshi Biosciences has built substantial in-house research and development infrastructure. The company operates research facilities and laboratories equipped for antibody discovery, protein engineering, and translational medicine. Its R&D philosophy centers on scientific innovation, with significant resources devoted to identifying novel biological targets and developing differentiated therapeutic candidates.

The company has developed proprietary technology platforms for antibody discovery and optimization, enabling it to generate high-quality biologic candidates. These platforms support the development of monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates.

Manufacturing

Junshi Biosciences has invested in large-scale, high-quality manufacturing capabilities to support both clinical development and commercial supply. The company operates manufacturing facilities designed to meet international quality standards, including compliance with Good Manufacturing Practice (GMP) requirements. This manufacturing capacity enables the company to produce biologics for domestic distribution as well as for export to international markets, supporting its global ambitions.

Global Collaborations and Partnerships

Junshi Biosciences has established strategic collaborations with major global pharmaceutical companies and organizations. Notable partnerships include its collaboration with Eli Lilly on COVID-19 neutralizing antibodies and its licensing agreement with Coherus BioSciences for the commercialization of toripalimab in the United States and Canada.

These partnerships extend the reach of Junshi's products beyond China and demonstrate the company's commitment to bringing its innovative therapies to patients worldwide. Through such collaborations, Junshi has been able to accelerate the global development and commercialization of its lead assets.

Commercialization

The company maintains a commercial organization responsible for the marketing, sale, and distribution of its approved products within China. This includes a dedicated sales force, medical affairs teams, and market access professionals who work to ensure that Junshi's therapies reach appropriate patient populations. The company also engages in efforts to have its products included in China's National Reimbursement Drug List (NRDL), which significantly expands patient access by providing insurance coverage.

Corporate Vision and Mission

Junshi Biosciences is driven by a mission to provide patients with trustworthy, affordable, and innovative medicines. The company aspires to become a globally respected biopharmaceutical enterprise, contributing to the advancement of human health through scientific innovation. Its focus on originality, quality, and international expansion positions it as a representative example of China's growing capability in the global biotechnology sector.

Significance in the Industry

Junshi Biosciences holds an important place in the evolution of China's biopharmaceutical industry. As the developer of the first domestic anti-PD-1 antibody and the first Chinese biologic to earn FDA approval in its category, the company has demonstrated that Chinese biotech firms can compete on the global stage in the development of complex, innovative biologics. Its combination of research depth, manufacturing capability, and international partnerships makes it a bellwether for the maturation of China's innovative drug ecosystem.